June 22, 2021 7:47am

Sustainability is at a crossroad

Pre-open indications: 5 BUYs: BLCM, BLUE, EDIT, NTLA, QURE; 1 SELL: CLLS; 1 Maintain SELL: BSTG

My version of the morning’s “indications” is about what you need to know; it’s what could happen or materialize after the opening and what might happen during the session

Subscription is coming, it’s not conscription but, an offer to join our collective of like-minded investors!  

Dow futures are UP +0.07% (+23 points), S&P futures are UP +0.13% (+6 point) and NASDAQ futures are UP +0.29% (+41 points)

 

U.S. stock futures were up but, fluctuating at least to the high side in Tuesday’s pre-open,

European stocks were mixed as volatile trading raged,

Asia-Pacific stocks were higher with shares in Japan leading gains among the region’s major markets.

 

Henry’omics:

The indexes and the cell and gene therapy sector equities recouped some of last week’s steep losses.

But, will it continue ...?

 

Data Docket: the Federal Reserve Bank of Philadelphia will release its non-manufacturing business data; the National Association of Realtors will publish existing home sales data for May and the Federal Reserve Bank of Richmond will release the results of its monthly Survey of Manufacturing Activity.

 

RegMed/Cell and Gene Therapy Earnings Scorecard Q1/21 LPS Results to date …  https://www.regmedinvestors.com/articles/11628

 

Monday’s evening’s recap: “take what we can get in this market as the cell and gene therapy sector is still feeling the post quadruple witching pressures.” … https://www.regmedinvestors.com/articles/11964

  • The Nasdaq closed UP +111.10 points (+0.79%);
  • The IBB closed up +0.90% and XBI closed up +0.91%
  • Sector volume SLIPPED back to a LOW profile with 5 of the 16-upside having higher than the 3-month average volume with the volume of 4 of 15-downside having higher than the 3-month average volume;
  • The CBOE Volatility Index (VVIX: INDEX) was down -2.78 points or -13.43% at 17.92;
  • Monday’s percentage (%) of the 16-upside were +0.06% (BLUE) to +4.66% (FIXX) while the 15-downside ranges from -0.09% (QURE) to -6.53% (AGTC);

Q2/21:

June: 9 positive and 5 negative closes

May:  8 positive, 12 negative closes and 1 holiday

April: 11 negative and 10 positive closes

Q1/21:

  • March: 10 positive, 12 negative and 1 neutral closes
  • February: 9 positive, 10 negative closes and 1 holiday
  • January: 10 positive, 9 negative closes and 1 holiday

 

Companies in my headlights – It’s your decision; I provide an idea and context:

The Biostage (BSTG) - Maintaining Sell – It’s about saying WHAT NEEDS to be written …

Biostage (BSTG) closed again flat at $1.21 with 572 shares traded after Friday with 333 shares traded after Thursday’s -$0.09 to $1.21 with 735 shares traded after Wednesday’s +$0.089 to $1.30 with 205 shares traded, Tuesday’s -$0.039 to $1.21 with 10,703 shares traded and last Monday’s flat at $1.25 with 2,305 shares traded.

Question#1: Will the annual meeting result in ANY news to/about the future of the company on Thursday, 6/24/21?

Question#2: The REAL question to be ANSWERED is WHO is advising them in ALL of these endeavors and was has been the effect and did/has affected conditions within the company and past issues that STILL remain UNRESOLVED?

MINORITY PUBLIC shareholders are waiting for the specific time, watching and weighing responses to MAINTAIN their RIGHTS.

 

The morning’s indications:

Maintaining BUY:

Bellicum Pharmaceuticals (BLCM) closed down -$0.06 to $3.21 after Friday’s +$0.09 to $3.27 and has a positive +$0.08 or +2.49% aftermarket indication.

bluebird bio (BLUE) closed up +$0.02 to $33.17 and has a positive +$0.23 or +0.69% aftermarket indication.

Editas Medicine (EDIT) closed up +$0.98 to $36.86 and has a positive +0.64 or +1.74% pre-market indication.

uniQure NV (QURE) closed down -$0.03 to $32.84 and has a positive +$0.15 or +0.46% aftermarket indication.

Intellia Therapeutics (NTLA) closed up +$3.30 to $79.22 and has a positive +$0.28 or +0.35% pre-market indication.

 

SELL:

Cellectis SA (CLLS) closed down -$0.34 to $14.51 and has a negative -$0.28 or -1.93% pre-market indication

 

The BOTTOM LINE: Cell and gene therapy sector equities are heading into headwinds and investors should buckle-up and use rallies to book profits.

I continue to MAINTAIN, this is a confused sector as sentiment rages and fades, momentum is usurped, fundamentals are being ignored.

When you’re on a roller coaster, the only thing you can be sure of is you’ll end up back where you started

Although, “I would consider new highs … to be SOLD into …complacency is in store as many investors actually get out to vacations (one indicator).”

A true contrarian thought …

My focus has always been “warning analysis” … my advice, trim and skim any new highs if one can!” I also see a number of lows that could be in the “pick-up” stock game.

My motto, never leave an investor uninformed about what I know!

 

Opinions expressed are those of the author and are subject to change, and not intended to be a forecast of future events, a guarantee of future results, nor investment advice.

Whether information or intelligence is good, bad or somewhere in between; I put into context what is relevant and useful for investors.  All investments are subject to risks. Investors should consider investment objectives.

Henry McCusker, the editor and publisher of RegMed Investors does not hold or have positions in securities referred to in this publication.